Angiostatic versus angiogenic chemokines in IPF and EAA.
BACKGROUND
Extrinsic allergic alveolitis (EAA) and idiopathic pulmonary fibrosis (IPF) share the presence of varying degree interstitial involvement and fibrosis. Vascular changes were often reported to accompany the development of fibrosis.


OBJECTIVE
The aim of our study was to examine the differences in angiostatic and angiogenic chemokine milieu in both diseases. Correlations between chemokine levels in bronchoalveolar lavage fluid (BALF), expression of chemokine receptors on CD4+ T cells (CXCR2, CXCR3) in BALF and HRCT pattern of the diseases were investigated.


METHODS
Sixteen patients with chronic EAA and 8 with IPF were enrolled to the study. Concentrations of interleukin (IL)-8, epithelial neutrophil activating protein (ENA)-78, interferon-gamma-inducible protein (IP)-10 and interferon-inducible T cell alpha chemoattractant (I-TAC) in BALF supernatants were quantified using Fluorokine MultiAnalyte profiling.


RESULTS
There was no significant difference in the BALF chemokine levels between the EAA and IPF group. IL-8 BALF concentrations correlate with the extent of fibrosis in both EAA and IPF (p<0.01). The IP-10 BALF concentrations do not correlate either with the HRCT alveolar or interstitial score and should be evaluated in the relationship with the disease course.


CONCLUSIONS
Both IL-8 and ENA-78 probably play a different role in IPF and chronic EAA pathogenesis. While we suggest ENA-78 as the marker of at least partial reversibility of the lung impairment in the EAA patients, IL-8 could be rather an indicator of continuous exposition to provoking agent in EAA patients. IL-8 might serve as a potential marker of early phase of IPF.
Martina
Sterclova
S
Department of Respiratory Medicine, Thomayer's University Hospital, Prague, Czech Republic. martinasafrankova@seznam.cz
Martina
Vasakova
V
Monika
Metlicka
M
Jan
Pavlicek
P
Libor
Kolesar
K
Ilja
Striz
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000542:Alveolitis, Extrinsic Allergic / Q000276:immunology* / Q000473:pathology; D015415:Biomarkers; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D054357:Chemokine CXCL10 / Q000032:analysis; D054371:Chemokine CXCL11 / Q000032:analysis; D054365:Chemokine CXCL5 / Q000032:analysis; D018925:Chemokines / Q000032:analysis*; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000276:immunology* / Q000473:pathology; D016209:Interleukin-8 / Q000032:analysis; D008168:Lung / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D019707:Receptors, Chemokine / Q000032:analysis; D055815:Young Adult
D015415:Biomarkers; C114753:CXCL10 protein, human; C515202:CXCL11 protein, human; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054365:Chemokine CXCL5; D018925:Chemokines; D016209:Interleukin-8; D019707:Receptors, Chemokine